Published in Pharmacol Rev on July 17, 2003
Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell (2011) 3.49
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat Chem Biol (2011) 2.42
Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol (2011) 2.02
Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Proc Natl Acad Sci U S A (2009) 1.70
Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood (2011) 1.52
ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance. PLoS Genet (2014) 1.48
Infrared spectroscopy and microscopy in cancer research and diagnosis. Am J Cancer Res (2011) 1.26
Cancer driver mutations in protein kinase genes. Cancer Lett (2008) 1.24
The kinase inhibitor imatinib mesylate inhibits TNF-{alpha} production in vitro and prevents TNF-dependent acute hepatic inflammation. Proc Natl Acad Sci U S A (2005) 1.23
Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem (2008) 1.21
Combination of two but not three current targeted drugs can improve therapy of chronic myeloid leukemia. PLoS One (2009) 1.20
Effect of cellular quiescence on the success of targeted CML therapy. PLoS One (2007) 1.18
A common phosphotyrosine signature for the Bcr-Abl kinase. Blood (2006) 1.16
SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene (2012) 1.15
Polyketal copolymers: a new acid-sensitive delivery vehicle for treating acute inflammatory diseases. Bioconjug Chem (2008) 1.14
BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem (2009) 1.11
The leukemic stem cell. Best Pract Res Clin Haematol (2007) 1.08
A novel mechanism for Bcr-Abl action: Bcr-Abl-mediated induction of the eIF4F translation initiation complex and mRNA translation. Oncogene (2006) 1.08
Virtual screening using molecular simulations. Proteins (2011) 1.05
Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem (2008) 1.04
Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract (2014) 1.04
Inhibition of Grb2 expression demonstrates an important role in BCR-ABL-mediated MAPK activation and transformation of primary human hematopoietic cells. Leukemia (2010) 1.03
Automated multidimensional phenotypic profiling using large public microarray repositories. Proc Natl Acad Sci U S A (2009) 1.02
IRF-4 functions as a tumor suppressor in early B-cell development. Blood (2008) 1.01
Emerging Roles of SIRT1 in Cancer Drug Resistance. Genes Cancer (2013) 0.97
Prediction of chemical-protein interactions network with weighted network-based inference method. PLoS One (2012) 0.97
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J (2012) 0.97
The immunoproteasome as a target in hematologic malignancies. Semin Hematol (2012) 0.97
The Effect of Imatinib Mesylate for Newly Diagnosed Philadelphia Chromosome-Positive, Chronic-Phase Myeloid Leukemia in Sub-Saharan African Patients: The Experience of Côte d'Ivoire. Adv Hematol (2010) 0.95
Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo. Br J Cancer (2010) 0.95
Validation of a high-content screening assay using whole-well imaging of transformed phenotypes. Assay Drug Dev Technol (2010) 0.94
Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol (2007) 0.93
Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol (2009) 0.93
Navigating the road toward optimal initial therapy for chronic myeloid leukemia. Curr Opin Hematol (2011) 0.93
Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle (2008) 0.91
Sunitinib impedes brain tumor progression and reduces tumor-induced neurodegeneration in the microenvironment. Cancer Sci (2015) 0.88
Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch (2004) 0.87
Exploring kinase inhibitors as therapies for human arenavirus infections. Future Virol (2008) 0.85
A novel function for platelet-derived growth factor D: induction of osteoclastic differentiation for intraosseous tumor growth. Oncogene (2011) 0.84
Overcoming CML acquired resistance by specific inhibition of Aurora A kinase in the KCL-22 cell model. Carcinogenesis (2011) 0.81
Imatinib spells BAD news for Bcr/abl-positive leukemias. Proc Natl Acad Sci U S A (2006) 0.81
Use of oncolytic viruses for the eradication of drug-resistant cancer cells. J R Soc Interface (2009) 0.80
Heterogeneity in chronic myeloid leukaemia dynamics during imatinib treatment: role of immune responses. Proc Biol Sci (2010) 0.79
Imatinib in chronic myeloid leukemia: an overview. Mediterr J Hematol Infect Dis (2014) 0.79
The emerging role of QSOX1 in cancer. Antioxid Redox Signal (2014) 0.79
Cell treatment and lysis in 96-well filter-bottom plates for screening Bcr-Abl activity and inhibition in whole-cell extracts. J Biomol Screen (2010) 0.79
Current concepts on the pathogenesis of the hypereosinophilic syndrome/chronic eosinophilic leukemia. Transl Oncogenomics (2006) 0.79
Comparative study for the efficacy, safety and quality of life in patients of chronic myeloid leukemia treated with Imatinib or Hydroxyurea. J Res Pharm Pract (2013) 0.79
A selective NMR probe to monitor the conformational transition from inactive to active kinase. ACS Chem Biol (2014) 0.78
Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World J Urol (2006) 0.78
[Hematological side effects of tyrosine kinase inhibition using imatinib]. Pathologe (2006) 0.78
Formulation and in vitro, in vivo evaluation of effervescent floating sustained-release imatinib mesylate tablet. PLoS One (2015) 0.76
The Jeremiah Metzger Lecture: intelligent design of cancer therapy: trials and tribulations. Trans Am Clin Climatol Assoc (2007) 0.76
RNAi screening identifies Trypanosoma brucei stress response protein kinases required for survival in the mouse. Sci Rep (2017) 0.76
Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death. Oncotarget (2016) 0.75
Two different point mutations in ABL gene ATP-binding domain conferring Primary Imatinib resistance in a Chronic Myeloid Leukemia (CML) patient: A case report. Biol Proced Online (2004) 0.75
Ensemble-based virtual screening: identification of a potential allosteric inhibitor of Bcr-Abl. J Mol Model (2017) 0.75
Proteome analysis of sheep B lymphocytes in the course of bovine leukemia virus-induced leukemia. Exp Biol Med (Maywood) (2017) 0.75
Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro. Exp Ther Med (2017) 0.75
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med (2002) 24.88
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol (2003) 11.33
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell (2009) 6.97
The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood (2004) 6.92
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res (2005) 5.98
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest (2010) 4.70
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood (2010) 4.69
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2006) 4.40
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood (2002) 4.00
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood (2002) 3.60
Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med (2013) 3.57
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol (2004) 3.51
Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol (2003) 3.38
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood (2008) 3.30
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell (2007) 3.23
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A (2006) 3.06
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J Clin Invest (2007) 2.91
Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood (2009) 2.87
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol (2002) 2.85
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood (2008) 2.76
Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell (2006) 2.69
Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell (2012) 2.69
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood (2003) 2.61
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res (2006) 2.61
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood (2004) 2.61
Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell (2011) 2.57
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 2.33
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol Cell Biol (2006) 2.28
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood (2012) 2.11
Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev (2005) 2.08
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood (2011) 2.07
Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res (2012) 2.01
BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships. Blood (2012) 2.01
Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res (2006) 1.97
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics. Ann Intern Med (2003) 1.95
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML. Blood (2006) 1.89
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms. Blood (2010) 1.83
RNAi screen for rapid therapeutic target identification in leukemia patients. Proc Natl Acad Sci U S A (2009) 1.81
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
Differential expression of novel tyrosine kinase substrates during breast cancer development. Mol Cell Proteomics (2007) 1.80
Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes. Leuk Res (2006) 1.76
Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells. Proc Natl Acad Sci U S A (2010) 1.75
Circumventing resistance to kinase-inhibitor therapy. N Engl J Med (2006) 1.75
Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease. Cancer Cell (2007) 1.72
Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood (2006) 1.65
Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl. Cancer Cell (2010) 1.64
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood (2008) 1.64
STI571 as a targeted therapy for CML. Cancer Invest (2003) 1.58
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures. Haematologica (2005) 1.56
The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile. Cancer Res (2011) 1.53
Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn (2011) 1.53
Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther (2011) 1.51
Applying the discovery of the Philadelphia chromosome. J Clin Invest (2007) 1.46
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med (2011) 1.45
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res (2007) 1.41
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem (2002) 1.40
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood (2002) 1.39
STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol (2002) 1.38
The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms. Biol Res Nurs (2006) 1.37
A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib. Blood (2009) 1.36
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood (2007) 1.33
Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia. Clin Cancer Res (2010) 1.32
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer (2009) 1.32
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res (2004) 1.30
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571). Cancer Res (2002) 1.29
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin Cancer Res (2005) 1.29
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer (2007) 1.29
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood (2009) 1.29
The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition. Blood (2013) 1.28
hOCT 1 and resistance to imatinib. Blood (2005) 1.28
AMN107: tightening the grip of imatinib. Cancer Cell (2005) 1.27
Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem (2008) 1.21
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy. J Mol Diagn (2008) 1.20
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins. Proc Natl Acad Sci U S A (2013) 1.19
BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood (2010) 1.19
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood (2008) 1.17
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol (2003) 1.17
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood (2007) 1.15
MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res (2010) 1.13
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma (2004) 1.12
Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia. Clin Cancer Res (2014) 1.12
Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia. Genome Res (2012) 1.11
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood (2002) 1.07
BCR-ABL-induced adhesion defects are tyrosine kinase-independent. Blood (2002) 1.05
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance. Mol Cell Biol (2008) 1.05
Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target. Proc Natl Acad Sci U S A (2013) 1.04
A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors. Cancer Res (2010) 1.02